SymbolCLAZF
NameCLARITAS PHARMACEUTICALS INC.
SectorUNDEFINED
RegionNorth America
Industry-
Address94903 United States CA 4040 Civic Center Drive Suite 200
Telephone+1 (888) 861-2008
Fax
Email
Websitehttps://claritaspharma.com/
IncorporationCA
Incorporated On2014
Employees
Fiscal Year12/31
Public Since
ExchangesOTC
AuditorBDO USA, LLP;
Audit StatusAUDITED
Reporting StatusInternational Reporting: Foreign Issuer - Not Listed on Foreign Exchange
CIK0001395961
Description

Claritas Pharmaceuticals is developing R-107, a nitric oxide-releasing compound, designed to augment the bodys own natural production of nitric oxide. Nitric oxide is a molecule produced naturally by most cell types in the body to.open blood vessels, reduce blood pressure, combat infection and heal wounds. R-107 is a liquid, nitric oxide-releasing compound that is designed to supplement the bodys own natural production of nitric oxide. R-107 can be administered by several methods, including orally by capsule, or by injection, or by nasal spray, or topically in an ointment. Depending on the mode of administration, R-107 can target the many diseases, disorders, and injuries that the bodys own natural nitric oxide targets. Our scientific team has built a reputation for global leadership in the science of nitric oxide medicine. Claritas is headquartered in San Francisco, CA, and has laboratory facilities in Beverly, MA that are fully-equipped with state-of-the-art systems to carry out analytical, bioanalytical, and synthetic chemistry activities.
.

Additional info from OTC:
Claritas Pharmaceuticals is developing R-107, a nitric oxide-releasing compound, designed to augment the bodys own natural production of nitric oxide. Nitric oxide is a molecule produced naturally by most cell types in the body to.open blood vessels, reduce blood pressure, combat infection and heal wounds. R-107 is a liquid, nitric oxide-releasing compound that is designed to supplement the bodys own natural production of nitric oxide. R-107 can be administered by several methods, including orally by capsule, or by injection, or by nasal spray, or topically in an ointment. Depending on the mode of administration, R-107 can target the many diseases, disorders, and injuries that the bodys own natural nitric oxide targets. Our scientific team has built a reputation for global leadership in the science of nitric oxide medicine. Claritas is headquartered in San Francisco, CA, and has laboratory facilities in Beverly, MA that are fully-equipped with state-of-the-art systems to carry out analytical, bioanalytical, and synthetic chemistry activities.
.

2024-08-28 05:18

Expert Market symbol attribute type Security_Name was changed. Previous value: -. New value: CLARITAS PHARMACICLS INC.

Read more
2024-08-27 08:14

OTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: CLARITAS PHARMACICLS INC.

Read more